![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108
https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-the-eu-as-add-on-treatment-to-ravulizumab-or-eculizumab-for-adults-with-rare-disease-pnh-who-have-residual-haemolytic-anaemia.html#:~:text=Voydeya%20(danicopan)%20has%20been%20approved,who%20have%20residual%20haemolytic%20anaemia.
https://www.fiercepharma.com/marketing/astrazenecas-alexion-takes-nmosd-awareness-campaign-long-form-new-film-highlighting
https://www.globenewswire.com/news-release/2024/04/08/2859605/0/en/Onco360-Has-Been-Selected-as-the-Sole-National-Specialty-Pharmacy-Partner-for-Voydeya-danicopan.html
https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-us.html#:~:text=Voydeya%20is%20a%20first%2Din,treated%20with%20a%20C5%20inhibitor.
https://www.fiercepharma.com/pharma/astrazenecas-rare-disease-unit-overcomes-fda-snub-expand-ultomiris-nmosd
https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-recommended-for-eu-approval.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108
https://www.biospace.com/article/fda-rejects-astrazeneca-s-ultomiris-label-expansion-in-nmosd/#:~:text=The%20FDA%20has%20denied%20AstraZeneca,disorder%2C%20the%20company%20announced%20Wednesday.
https://www.onclive.com/view/the-evolving-treatment-landscape-in-paroxysmal-nocturnal-hemoglobinuria
https://www.pharmatimes.com/news/astrazenecas_ultomiris_approved_in_japan_for_prevention_of_relapses_in_patients_with_nmosd_1492208
https://www.pharmaceutical-technology.com/news/astrazenecas-ultomiris-japanese-approval-nmosd/
https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd.html
https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-recommended-for-nmosd-eu-approval.html
https://www.pharmaceutical-technology.com/news/ec-alexion-ultomiris-myasthenia-gravis/
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/ultomiris-approved-in-eu-for-gmg.html
https://www.biospace.com/article/releases/danicopan-alxn2040-add-on-to-ultomiris-ravulizumab-cwvz-or-soliris-eculizumab-met-primary-endpoint-in-alpha-phase-iii-trial-for-patients-with-paroxysmal-nocturnal-hemoglobinuria/?s=69
https://www.biospace.com/article/astrazeneca-makes-waves-in-japan-with-approvals-for-tagrisso-ultomiris-and-lynparza/
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/ultomiris-approved-in-japan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis.html
https://www.prnewswire.com/news-releases/argenxs-vyvgart-and-alexions-ultomiris-go-toe-to-toe-in-generalized-myasthenia-gravis-according-to-spherix-global-insights-301611961.html
https://endpts.com/on-a-roll-astrazeneca-flags-looming-approvals-for-three-big-drug-franchises/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108
https://www.fiercepharma.com/pharma/roche-chugai-astrazeneca-alexion-settle-ultomiris-patent-lawsuit
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108
https://www.astrazeneca.com/media-centre/press-releases/2021/ultomiris-accepted-for-fda-priority-review-for-gmg.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108
https://www.businesswire.com/news/home/20210607005638/en/%C2%A0Alexion-Announces-FDA-Approval-of-ULTOMIRIS%C2%AE-ravulizumab-cwvz-for-Children-and-Adolescents-with-Paroxysmal-Nocturnal-Hemoglobinuria-PNH#:~:text=ULTOMIRIS%2C%20a%20long%2Dacting%20C5,children%20and%20adolescents%20with%20PNH.&text=It\'s%20exciting%20to%20finally%20have,who%20are%20diagnosed%20as%20children.%E2%80%9D
https://www.globenewswire.com/news-release/2021/05/12/2228361/0/en/Apellis-to-Present-Long-Term-Pegcetacoplan-Data-in-PNH-at-the-European-Hematology-Association-Virtual-Congress.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108
https://www.fiercepharma.com/marketing/alexion-wins-nice-backing-for-ultomiris-pnh-as-atypical-hus-decision-awaits
http://www.pmlive.com/pharma_news/alexion_and_nice_agree_confidential_discount_for_ultomiris_use_on_the_nhs_1367231
https://pharmaphorum.com/news/nice-recommends-alexions-long-acting-ultomiris-for-pnh/#:~:text=NICE%20has%20recommended%20Alexion's%20long,schedule%20after%20a%20loading%20phase.
https://www.thepharmaletter.com/article/nice-backs-ultomiris-for-adult-patients-with-pnh?__cf_chl_jschl_tk__=05ae265e2d7a30fa74c7378e0e3af7d7c487fac8-1618567066-0-Ad1i1wglZy82v3-Wl8s_PG0vNpjxq7oB7nseaMD9p-J-C_oviWJgqCsi2mXkm3hoF6rtpX6NcUE4tNfT1vhsgxO2_rvEXM7nwYYkHDdGPjYl7agdXL102AeTooXdrYxbJjyZiIVxAJ2nhHp5_WqrJKIwQyVACv7EjBUdHMsmksYckO89ifFBDndScttzTEP58xLTACa3wQuyDRmorodt0ArT5Fmv_eTNYUZTgayyVRlVMEnIK7iLCL4isa-oNl9mqeVzfKKonYt4DMj2MWdg7LdqqAQD3CmvZES0ZLB8mu7wr-C0mLn2q6E-6xJxXG7EQxutFK07akwjeLKUBxMg8ehozO_45N2Aw0SC10qys-tyxIbMyH6gFnqpZumJwKX2A_EXnellUtjOYP45GmIwUWsieErV5nuRg_RD4pLrSLilyOMvECfQzvUwx4HW42CpSHzdHx4rj_5BrO5RwQb9cT3le47WU_4TULwJdrrbAhTDE3fVAM4gngcpN1xqE8FOMw
https://www.bloomberg.com/press-releases/2021-01-13/alexion-provides-update-on-phase-3-study-of-ultomiris-ravulizumab-cwvz-in-hospitalized-patients-with-severe-covid-19
https://globalarbitrationreview.com/korean-biotech-company-liable-in-gene-therapy-dispute